Articles tagged with Type 1 Diabetes
Researchers at La Jolla Institute identified specific T cells that trigger type 1 diabetes in humans for the first time in human tissues. The study provides a crucial step in interrupting the disease process and highlights CD8 T cells as key players.
Researchers have discovered a protein called Islet Homeostasis Protein (IHoP) that regulates blood sugar levels by balancing insulin and glucagon. The protein's presence helps maintain healthy glucose levels, while its absence leads to increased glucagon and insulin resistance.
The REMOVAL study aims to test whether metformin can prevent or reduce the risk of cardiovascular complications in people with type 1 diabetes. The five-year trial will follow 500 patients and examine the effects of metformin on blood glucose control, treatment satisfaction, and other complications.
Researchers at Joslin Diabetes Center have identified a critical diagnostic marker that differentiates type 1 from type 2 diabetes in young Asian Americans, highlighting the importance of insulin resistance. The study also found physical differences in Asian patients with diabetes that should inform treatment recommendations.
Researchers at La Jolla Institute create cellular movies showing the destruction underlying type 1 diabetes in real-time, providing new insights into disease process and potential therapeutic directions. The studies use two-photon microscope to illuminate cell processes previously extrapolated from photos or lab experiments.
Researchers found that intensive diabetes therapy can preserve kidney function in patients with type 1 diabetes, preventing impaired kidney function and kidney failure. The study's results demonstrate the importance of maintaining good glucose control early in the course of type 1 diabetes to prevent long-term kidney complications.
A long-term study found that early, intensive glucose-lowering therapy in type 1 diabetes patients prevented impaired glomerular filtration rates and reduced the risk of end-stage kidney disease. Participants who received intensive therapy showed a 50% lower risk of developing impaired GFR over a median follow-up period of 22 years.
Researchers found that connexin 36 protects mouse pancreatic beta-cells against apoptosis triggered by immune molecules prevalent at the onset of Type 1 diabetes. Promoting connexin 36 expression and function could provide a therapeutic strategy to protect beta-cells from immune system attack.
A $3.9 million grant will enable research to identify protective factors that prevent diabetes complications in long-term insulin-dependent diabetes patients. The study aims to find biomarkers and therapeutic agents to halt diabetic retinopathy and nephropathy, which significantly impact lifespan and quality of life.
Researchers discover a compound that prevents Type 1 diabetes in mice and has similar effects on human cells from diabetic patients. The finding signals a new direction in fighting the disease and other autoimmune disorders.
A group of international diabetes researchers have been awarded $4.5 million to engineer an artificial pancreas system that can monitor and adapt to the body's complex physiological changes. The system aims to improve quality of life for patients with type 1 diabetes by treating the condition in their natural environment.
Researchers have identified a non-classical form of fetal immune thrombocytopenia that can lead to miscarriage and habitual abortion. The condition is characterized by excessive platelet activation and blood clot formation in the placenta. New treatments targeting this condition have been suggested, offering hope for women affected by it.
The University of California San Diego is awarded a $5.9 million grant to study kidney complications related to type 1 and type 2 diabetes. The researchers aim to challenge current dogma by examining the link between mitochondrial function, metabolic alterations, and kidney disease.
A large-scale genetic study has uncovered new genes associated with type 1 diabetes, a condition affecting 200 million people worldwide. The research adds to knowledge of gene networks involved in the origin of this complex disorder.
Hebrew University researchers have identified a key signal that prompts production of insulin-producing beta cells, which may help restore or increase beta cell function in people with type 1 diabetes. The study found that glucose levels trigger the regeneration of beta cells through a specific enzyme, glucokinase.
Researchers at St. Michael's Hospital discovered that GABA injections prevented and reversed Type 1 diabetes in mice by regenerating insulin-producing cells and decreasing the immune system's attack on them. This breakthrough finding offers new avenues for prevention and treatment of Type 1 diabetes.
A study by Dr Jay S Skyler and colleagues found that abatacept slows the loss of insulin-producing beta-cells in type 1 diabetes patients, but only for the first six months. The treatment helps modulate T-cell activation, resulting in higher C-peptide levels.
A vaccine targeting glutamic acid decarboxylase (GAD) failed to preserve insulin production in patients with newly diagnosed type 1 diabetes. Researchers suggest that the vaccine may be beneficial for preventing or delaying the onset of the disease, but should not be used in clinical practice.
Researchers found that a strawberry a day may keep doctors away, including neurologists, endocrinologists, and oncologists. Fisetin, a flavonoid compound, reduced complications of diabetes, anxiety-related behaviors, and high blood sugar levels in mice.
Researchers have found that low doses of BCG can temporarily reverse type 1 diabetes in human patients by eliminating autoreactive T cells. A Phase II trial is now underway to test the effectiveness of this approach.
Research finds that adolescents and young adults with type 1 diabetes have increased risk of heart attack and stroke due to atherosclerosis in the carotid arteries. The study aims to improve glycemic control and reduce cardiovascular risk factors to prevent cardiovascular disease.
A new study found that people diagnosed with type 1 diabetes can expect to live up to 15 years longer than previously thought. The study, published in the American Diabetes Association's 71st Scientific Sessions, analyzed data from a 30-year prospective study and found a significant improvement in life expectancy among participants.
Mayo Clinic researchers are developing an artificial pancreas that will deliver insulin automatically and with individualized precision, reducing the need for daily insulin dosing and finger pricks. The system includes a blood sugar monitor, automatic insulin pump, activity monitors, and a central processing unit.
The DIAPREV-IT study, a three-year project funded by the Juvenile Diabetes Research Foundation, aims to vaccinate healthy children at high risk of developing type 1 diabetes. The researchers believe that vaccinating earlier in the disease process can save more beta cells and increase the vaccine's effectiveness.
Researchers at Rensselaer Polytechnic Institute have created a closed-loop artificial pancreas that can automatically monitor blood sugar levels and administer insulin to individuals with Type 1 diabetes. The device aims to reduce the guesswork involved in daily insulin management, which is crucial for maintaining stable glucose levels.
Georgia Health Sciences University researchers are exploring whether low levels of interleukin-1 receptor antagonist (IL-1ra) can identify children at risk for developing type 1 diabetes. They also plan to investigate using IL-1 inhibitors to prevent the disease.
Despite significant advances in kidney care, type 1 diabetes patients with kidney dysfunction continue to face increased risks of kidney failure and heart-related death. New therapies are needed to retard progression to end-stage renal disease.
Researchers analyzed data from 592 patients with type 1 diabetes and macroalbuminuria to identify predictors of End-Stage Renal Disease (ESRD) and pre-ESRD mortality. The study found that poor glycemic control increases ESRD risk but not pre-ESRD mortality, while improved lipid management affects both outcomes.
Researchers at the Medical College of Wisconsin found that children with type 1 diabetes often develop early cardiovascular disease before puberty, characterized by stiffer blood vessels and vascular inflammation. The study highlights the need for long-term studies to monitor the progression of these changes in young patients.
The European Diabetes Research Network, funded by the EU, will investigate the possible role of virus infection in causing type 1 diabetes. The network aims to develop a vaccine to prevent diabetes in children and improve diagnosis and patient care.
UT Southwestern researchers found that eliminating glucagon action can restore glucose tolerance to normal in mice with type 1 diabetes. This suggests a potential 'cure' for the disease, as insulin would no longer be necessary.
A La Jolla Institute team has validated a computer model's ability to predict key information on nasal insulin treatment regimens in type 1 diabetes. The platform accurately predicted biomarker onset and therapeutic outcome, confirming its potential as a valuable research tool.
A Finnish study found that infant feeding with a highly hydrolyzed casein-based formula reduced the emergence of diabetes-predictive autoantibodies by about 50% among high-risk children. The study suggests that early dietary intervention can substantially reduce the initiation of the disease process leading to Type 1 diabetes.
Researchers used selective breeding of mice to identify a novel gene, AK005651, associated with type 1 diabetes susceptibility. A recombination hotspot helped stack the DNA deck in favor of finding this gene, revealing new clues about genomic mechanisms underlying T1D.
Researchers at UT Southwestern Medical Center found that infusing leptin into the brain of mice with type 1 diabetes reversed lethal consequences and improved metabolism. The study suggests a novel role for the brain in mediating beneficial actions of leptin, potentially leading to new therapies for individuals with type 1 diabetes.
A UBC-CFRI study found elevated levels of Th17 cells in young patients with type 1 diabetes, suggesting a potential target for new therapies. The discovery may lead to innovative treatments for childhood diabetes.
A crowdsourcing experiment, called the Challenge, has selected 12 pioneering ideas for attacking Type 1 Diabetes. These ideas were proposed by a diverse group of people, including patients, students, and researchers from various backgrounds.
UC San Diego researcher Maike Sander leads a team in developing replacement insulin-producing beta cells from patient-derived induced pluripotent stem cells. The goal is to create a cell-based approach for treating type 1 diabetes, providing patients with insulin independence and reduced risk of hypoglycemia.
A multi-center team of scientists from OHSU is part of the prestigious Beta Cell Biology Consortium, aiming to develop a cell-based therapy for insulin delivery in type 1 diabetes patients. The researchers hope to produce abundant quantities of functional human insulin-producing beta cells that can be used for transplantation.
Novo Nordisk's decision to withdraw Mixtard 30 insulin could add £9 million to the NHS drugs bill in England, affecting 90,000 patients with type 1 and 2 diabetes. Alternative biphasic insulins are more expensive and may cause disruption to patient care.
Researchers found that adding a continuous blood sugar sensor to an insulin pump improved blood sugar control, with significant decreases in A1c levels and no increase in severe hypoglycemia. The study's findings suggest that this technology can help patients of all ages manage their diabetes effectively.
A new study finds that death rates from type 1 diabetes have steadily improved over the past few decades, with more recent diagnoses showing a lower risk of mortality. However, women and African-Americans are still disproportionately affected, with higher mortality rates compared to men and Caucasians.
A study by researchers funded by JDRF found that the serotonin hormone increases insulin-producing beta cells during pregnancy. This discovery could lead to the development of new drugs to promote beta cell regeneration in people with type 1 diabetes, offering a potential cure for the disease.
The Phase I trial found low-dose, multi-dosing regimens of BCG vaccination safe in individuals with type 1 diabetes, with no severe reactions reported. A Phase II clinical trial is planned to investigate the safety and efficacy of BCG vaccination as a therapeutic agent for type 1 diabetes prevention or reversal.
A study found that high HDL levels in women with type 1 diabetes increased the risk of heart disease, while low levels actually decreased risk. The researchers suggest that too much good cholesterol may not always be protective and could even be harmful.
A study by the University of Pittsburgh Graduate School of Public Health found that consuming higher amounts of omega-3 fatty acids does not lower heart disease risk in women with type 1 diabetes. Men with the same condition had a lower rate of heart disease at higher omega-3 intake levels.
Researchers found that early asymptomatic kidney damage in type 1 diabetes leads to a significant increase in mortality, while normal kidneys offer no increased risk of death. The study involved 658 participants and followed them for 20 years.
A new study found that vitamin C and E supplements do not prevent pre-eclampsia in pregnant women with type 1 diabetes, but may benefit those with low antioxidant status. The supplement did not cause harm to mothers or babies.
Researchers developed an experimental cure for Type 1 diabetes using gene therapy, which successfully reversed the disease in about half of nonobese diabetic mice. The treatment protected new beta cells from autoimmune attack by adding a protective gene, allowing them to function normally.
Researchers have discovered that type 1 diabetes patients experience a 10-fold increase in islet cell replication after diagnosis. This finding suggests that immune cells are involved in triggering the replication process. The study offers promising results for developing a therapy to encourage beta cells to reproduce and produce insulin.
Researchers have found a statistically significant association between enteroviral infection and diagnosis of type-1 diabetes in children, with 83% of patients testing positive for enteroviral DNA. The study suggests that different enterovirus types may represent a significant biomarker for early-stage juvenile diabetes.
Researchers found a molecular link between genetic mutations and type 1 diabetes, identifying a critical new target for intervention. The study's findings suggest a way to break 'tolerance' in the immune system, potentially leading to novel antibody or small molecule therapies.
Researchers developed a nanovaccine to stop aggressive immune attack on beta cells, restoring normal blood sugar levels in humanized mouse models. The treatment targeted specific immune cells without compromising the rest of the immune system.
A new study found that teenagers with type 1 diabetes are more likely to adhere to their treatment plan if their parents monitor their care and maintain a positive parent-adolescent relationship. The study revealed a decline in parental involvement as the adolescent grows older, which relates to decreased adherence to treatment.
Scientists found that alpha cells can spontaneously reprogram into beta cells, restoring insulin production and potentially treating type 1 diabetes. The study demonstrated that removing nearly all beta cells allowed the pancreas to regenerate new ones, offering a new strategy for regenerating insulin-producing cells.
Researchers at EVMS Strelitz Diabetes Center have received a $1.076 million grant from the Department of Defense to develop new treatments for Type 1 diabetes, focusing on regeneration of insulin-producing beta cells and neutralizing the immune system's attack. The goal is to create a functional cure using a combination therapy regimen.
Researchers at UT Southwestern Medical Center found that leptin administration showed better management of blood-sugar variability and lipogenesis, the conversion of simple sugars into fatty acids. Leptin therapy also reduced food intake and increased lean body mass in non-obese type 1 diabetic mice.
Researchers found that some genes have opposing effects on the risk of developing both autoimmune diseases, while others may increase the risk for both. The study suggests a possible genetic switch that could be triggered by specific infectious agents.
Researchers at the University of Cambridge found that first-generation artificial pancreas systems can lower risk of low blood sugar emergencies while sleeping and improve diabetes control. The study showed improved target blood glucose levels, minimized low blood sugars, and reduced hypoglycemia.
A new study published by researchers at Eastern Virginia Medical School has identified a protein-based enzyme called 12-Lipoxygenase (12-LO) as a key player in the development of Type 1 diabetes. The enzyme produces specific lipids that cause inflammation and lead to beta cell death, highlighting a potential target for new therapies.